We like a good news story, especially where incurable cancer is concerned. You can read this Daily Mail article here . It reports on great results with two new immunotherapy drugs used together in the USA
Jon starts on just one of these drugs – Nivolumab – next week. #cancer #facingup2kc #hope #fingerscrossed Past research has found that there are certain similarities between treating melanoma and renal cell carcinoma (RCC), but the RCC research and science is some way behind at the moment. Cost and successful trials are so important because evidence based treatment is the way forward and there can be significant side effects for patients to cope with.
The research project we are supporting is so important, to help us please donate here, or text JBKC10 £3, £5, or £10 to 70070. Thank you very much. We will let you know how Jon’s treatment goes, if he tolerates Nivolumab, treatment may last twelve months.